Telix Pharmaceuticals Limited focused on on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), has partnered up with Advanced Nuclear Medicine Ingredients SA (ANMI).
Telix and ANMI will together work on ANMI’s 68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit (Kit), a technology for imaging and staging metastatic prostate cancer, in the US market. Telix will also offer the Kit worldwide.
PSMA-11 (also known as DKFZ-112) is a small molecule that binds to prostate-specific membrane antigen (PSMA), a well-validated target that is highly expressed in both localised and metastatic prostate cancer, including castrate-resistant prostate cancer.
Telix Co-Founder and CEO Dr. Christian Behrenbruch said: “ANMI’s ‘shake and inject’ kit allows for the rapid, room-temperature labelling of the PSMA-11 ligand with gallium. This has become a well-proven approach for imaging prostate cancer and ANMI’s technology makes the process extremely efficient in the clinical setting. ANMI’s radiochemists are the best and brightest in the industry and we are pleased to be working with the team to tackle prostate cancer.”
ANMI Co-Founder and CEO Ludovic Wouters said: “Prostate cancer affects one in eight men in the US3 and the market opportunity is very significant. We are pleased to be working with Telix to deliver our solution to patients in the US.” ANMI Co-Founder and CSO Dr. Sam Voccia added, “Telix is building a portfolio of diagnostic and therapeutic urology products that we believe will help to drive physician interest and market share for our products.”
As part of the deal, Telix and ANMI will form a joint-venture (JV) company, with ANMI selling Kits exclusively to the JV for the US Market. Telix will act as the sales and marketing partner to the JV, via the its US subsidiary.
Image: Telix Pharmaceuticals